The utmost in multiplex functionality and sensitivity.
Cambridge Biomedical has optimized and validated multiple biomarker assays using the Meso Scale Discovery® (MSD) platform. The MSD technology facilitates the detection of biomarkers such as cytokines and intracellular signaling proteins within complex sample matrices.
MSD’s core technology combines the use of electro-chemiluminescence and MULTI-ARRAY® technology to provide both multiplex functionality and sensitivity. MSD’s electro-chemiluminescence detection technology utilizes SULFO-TAG™ conjugated labels which emit light upon electro-chemical stimulation, initiated at the electrode surfaces of MULTI-ARRAY and MULTI-SPOT® microplates.
Electro-chemiluminescence offers significant advantages over traditional ELISA assays including low background, signal amplification, improved sensitivity and dynamic range. In a multiplex array, the MSD platform facilitates the detection of up to ten analytes from a single sample. The MSD catalog includes a large selection of single and multiplex kits for profiling biomarkers, cell signaling pathways as well as other applications.
Cambridge Biomedical and Btk
Cambridge Biomedical scientists have significant experience in MSD assay transfer, development, and optimization as well as sample testing in support of clinical trials at multiple stages. Among the clinical studies that Cambridge Biomedical has many contributions to include receptor occupancy assays such as free uninhibited Btk target site occupancy in human B cell lysates.
Check out our published work.
Cambridge Biomedical currently operates two Meso Scale Discovery QuickPlex SQ 120 units along with one Sector Imager 6000 with Discovery Workbench® 4.0 software which are GLP-compliant (21 CFR Part 11).